Search
Contact
Score Calculators
Research
Research by funder
EF CLIF
European Union
Other funders
Private companies
Research by topic
Liver pathophysiology
Clinical course of chronic liver disease
Biomarker discovery
Therapeutic innovation
Publications
Flagship projects
Observational studies
ACLARA
CANONIC
CHANCE
COBALT
PREDICT
Translational research
DISCOVERY
Grifols Chair Program
People
Research infrastructure
News & Events
About us
Our history
Our strategy
Our organization
Governance
Executive Team
Committees
Working Groups
Our network
EASL-CLIF Consortium
European Network for Translational Research
Global Projects
Our partners
Annual Reports
Contact
Research
Research by funder
EF CLIF
European Union
Other funders
Private companies
Research by topic
Liver pathophysiology
Clinical course of chronic liver disease
Biomarker discovery
Therapeutic innovation
Publications
Flagship projects
Observational studies
ACLARA
CANONIC
CHANCE
COBALT
PREDICT
Translational research
DISCOVERY
Grifols Chair Program
People
Research infrastructure
News & Events
About us
Our history
Our strategy
Our organization
Governance
Executive Team
Committees
Working Groups
Our network
EASL-CLIF Consortium
European Network for Translational Research
Global Projects
Our partners
Annual Reports
Contact
Biomarker discovery
Ongoing research
A possible role for FXR polymorphisms in the etiopathogenesis of acute decompensation of cirrhosis and ACLF: An observational study within CANONIC and PREDICT
Biomarkers of renal tubular damage in predicting response to terlipressin and albumin in patients with hepatorenal syndrome
CHANCE: Liver transplantation in patients with cirrhosis and severe acute-on-chronic liver failure – Indications and outcomes
DECISION: Decompensated cirrhosis – Identification of new combinatorial therapies based on systems approaches
Glycomics-based biomarkers for diagnosis and prognosis in ACLF
Grifols Chair Program
Identification of albumin receptors and characterization of albumin intracellular trafficking in human peripheral blood mononuclear cells
MICROB-PREDICT: Microbiome-based biomarkers to predict decompensation of liver cirrhosis and treatment response
Molecular markers to predict chronic liver failure and to explore its mechanistic pathways in decompensated cirrhosis
Meet the principal investigators working on biomarker discovery
Paolo Angeli
MD, PhD
William Bernal
MD
Joan Clària
PhD
Cornelius Engelmann
MD, PhD
Javier Fernández
MD, PhD
Thierry Gustot
MD, PhD
Rajiv Jalan
MD, PhD
Wim Laleman
MD, PhD
Salvatore Piano
MD, PhD
Pierre-Emmanuel Rautou
MD, PhD
Loredana Saveanu
MD, PhD
Jonel Trebicka
MD, PhD
Xavier Verhelst
MD, PhD
Related News
16 October 2026
Multi-ancestry genome-wide association study identifies gene variant linked to renal impairment in decompensated cirrhosis
17 June 2026
EF CLIF partners with Boehringer Ingelheim to unlock new paths for patients with decompensated cirrhosis
5 June 2026
Multi-omics study identifies a disrupted metabolic pathway linked to acute-on-chronic liver failure progression and death in advanced cirrhosis
15 May 2026
A lipid toxin linked to immune paralysis may drive infections and acute-on-chronic liver failure in acutely decompensated cirrhosis
View all news